Page 65 - AN-3-1

Advanced Neurology Dementia with Lewy bodies and substance misuse

induced hyponatremia in older adults. Consult Pharm. doi: 10.1016/S0072-9752(07)01224-9
2016;31(3):139-150.
41. Vanmechelen E, Vanderstichele H, Hulstaert F, et al.
doi: 10.4140/TCP.n.2016.139 Cerebrospinal t and B-amyloid in dementia disorders. Mech
Ageing Dev. 2001;122(16):2005-2011.
30. Deckers K, Camerino I, van Boxtel MP, et al. Dementia risk
in renal dysfunction: A systematic review and meta-analysis doi: 10.1016/S0047-6374(01)00304-9
of prospective studies. Neurology. 2017;88(2):198-208. 42. Tariciotti L, Casadei M, Honig LS, et al. Clinical experience
doi: 10.1212/WNL.0000000000003482 with cerebrospinal fluid Aβ42, total and phosphorylated
tau in the evaluation of 1,016 individuals for suspected
31. Butterworth RF. The role of liver disease in alcohol-induced dementia. J Alzheimers Dis. 2018;65(4):1417-1425.
cognitive defects. Alcohol Health Res World. 1995;19(2):122-129.
doi: 10.3233/jad-180548
32. Jan K. Wernicke encephalopathy: (MRI) picture
worth a thousand words. Oxf Med Case Reports. 43. Kac PR, Gonzalez-Ortiz F, Simrén J, et al. Diagnostic value of
2018;2018(5):omy013. serum versus plasma phospho-tau for Alzheimer’s disease.
Alzheimers Res Ther. 2022;14(1):65.
doi: 10.1093/omcr/omy013
doi: 10.1186/s13195-022-01011-w
33. Koenig AM, Nobuhara CK, Williams VJ, Arnold SE.
Biomarkers in Alzheimer’s, frontotemporal, lewy body, 44. Rodríguez-Blázquez C, Martinez-Martin P, Forjaz M, Kurtis
and vascular dementias. Focus (Am Psychiatr Publ). M, Balestrino R. Rating scales in movement disorders. Front
2018;16(2):164-172. Neurol. 2018;9:435.
doi: 10.1176/appi.focus.20170048 doi: 10.3389/fneur.2018.00435
34. Kim HW, Hong J, Jeon JC. Cerebral small vessel disease and 45. Nasreddine Z, Phillips N, Bédirian V, et al. The Montreal
Alzheimer’s disease: A review. Front Neurol. 2020;11:927. cognitive assessment, MoCA: a brief screening tool for mild
cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699.
doi: 10.3389/fneur.2020.00927
doi: 10.1111/j.1532-5415.2005.53221.x
35. Qian X, Xiao S. Peripheral nerve conduction study
in early cognitive impairment of Alzheimer’s disease: 46. Hyman B, Phelps C, Beach T, et al. National institute on aging-
Neuropsychiatry and behavioral neurology/Mild cognitive Alzheimer’s association guidelines for the neuropathologic
impairment/Early symptomatic disease. Alzheimers Dement. assessment of Alzheimer’s disease. Alzheimers Dement.
2012;8(1):1-13.
2020;16(s6):e041671.
doi: 10.1016/j.jalz.2011.10.007
doi: 10.1002/alz.041671
47. Farrer M. The genetics and molecular biology of alpha-
36. Nakajima M, Kawamura K, Akiba C, et al. Differentiating synuclein. Handb Clin Neurol. 2008;89:313-319.
comorbidities and predicting prognosis in idiopathic
normal pressure hydrocephalus using cerebrospinal fluid doi: 10.1016/S0072-9752(07)01230-4
biomarkers: A review. Croat Med J. 2021;62(4):387-398. 48. Braak H, Del Tredici K, Rüb U, de Vos R, Jansen Steur EN,
doi: 10.3325/cmj.2021.62.387 Braak E. Staging of brain pathology related to sporadic
Parkinsons disease. Neurobiol Aging. 2003;24(2):197-211.
37. Janssen JC, Godbolt AK, Ioannidis P, Thompson EJ,
Rossor MN. The prevalence of oligoclonal bands in the doi: 10.1016/s0197-4580(02)00065-9
CSF of patients with primary neurodegenerative dementia. 49. Lowe J. Neuropathy of dementia with lewy bodies. Handb
J Neurol. 2004;251(2):184-188. Clin Neurol. 2008;89:321-330.
doi: 10.1007/s00415-004-0296-4 doi: 10.1016/S0072-9752(07)01231-6
38. Santaella A, Kuiperij HB, van Rumund A, Esselink RAJ, 50. Eriksen J, Zehr C, Lewis J. Biological models of
Bloem BR, Verbeek MM. Cerebrospinal fluid myelin basic neurodegenerative disorders. Handb Clin Neurol.
protein is elevated in multiple system atrophy. Parkinsonism 2008;89:173-188.
Relat Disord. 2020;76:80-84.
doi: 10.1016/S0072-9752(07)01216-X
doi: 10.1016/j.parkreldis.2020.06.004
51. Gomez-Isla T, Spires T, De Calignon A, Hyman B.
39. De Lorenzi D, Mandara MT. The central nervous system. Neuropathy of Alzheimer’s disease. Handb Clin Neurol.
Can Feline Cytol. 2010:325-365. 2008;89:233-243.
doi: 10.1016/B978-141604985-2.50019-0 doi: 10.1016/S0072-9752(07)01222-5
40. Zetterberg H, Blennow K. Biological CSF markers of 52. Hardy J, Gwinn-Hardy K. The relationship between
Alzheimer’s disease. Handb Clin Neurol. 2008;89:261-268. nosology, etiology and pathogenesis in neurodegenerative

Volume 3 Issue 1 (2024) 13 https://doi.org/10.36922/an.2232